Gossamer Bio, Inc.
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Countdown
237days
FDA decision · Mar 1, 2027
What's at stake
The FDA's approval decision on seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) is due Mar 1, 2027. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“If the NDA is accepted for filing, seralutinib could be eligible for FDA approval in the third quarter of 2027.”